RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company SCYNEXIS, Inc. today announced that it has received a payment from Merck & Co., Inc. for achieving a preclinical milestone resulting from a collaboration to discover and develop novel oncology agents.
